Financhill
Sell
23

ARVN Quote, Financials, Valuation and Earnings

Last price:
$7.77
Seasonality move :
-16.08%
Day range:
$7.35 - $7.66
52-week range:
$5.90 - $33.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.28x
P/B ratio:
0.84x
Volume:
1.7M
Avg. volume:
1.9M
1-year change:
-76.81%
Market cap:
$554M
Revenue:
$263.4M
EPS (TTM):
-$0.66

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARVN
Arvinas
$34.4M -$0.89 -55% -82.24% $19.36
AGIO
Agios Pharmaceuticals
$9.5M -$1.78 10.66% -6.63% $51.71
ALNY
Alnylam Pharmaceuticals
$646.1M $0.07 -3.52% -58.59% $330.77
FOLD
Amicus Therapeutics
$146.7M $0.04 16.44% -80% $15.82
OGN
Organon &
$1.6B $0.94 -3.44% 24.83% $13.33
PFE
Pfizer
$13.5B $0.57 -3.34% 10.12% $29.23
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARVN
Arvinas
$7.59 $19.36 $554M -- $0.00 0% 1.28x
AGIO
Agios Pharmaceuticals
$39.99 $51.71 $2.3B 3.56x $0.00 0% 62.49x
ALNY
Alnylam Pharmaceuticals
$322.81 $330.77 $42.1B -- $0.00 0% 17.67x
FOLD
Amicus Therapeutics
$6.07 $15.82 $1.9B -- $0.00 0% 3.42x
OGN
Organon &
$9.63 $13.33 $2.5B 3.34x $0.02 8.93% 0.40x
PFE
Pfizer
$24.61 $29.23 $139.9B 17.83x $0.43 6.91% 2.25x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARVN
Arvinas
0.08% 2.064 0.1% 4.50x
AGIO
Agios Pharmaceuticals
-- 3.428 -- 17.12x
ALNY
Alnylam Pharmaceuticals
89.88% 0.837 2.91% 2.84x
FOLD
Amicus Therapeutics
66.87% -0.424 15.55% 2.22x
OGN
Organon &
94.29% -0.945 233.18% 0.77x
PFE
Pfizer
40.42% 0.055 42.59% 0.88x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARVN
Arvinas
-- $71.4M -7.71% -7.72% 37.82% -$89.3M
AGIO
Agios Pharmaceuticals
$7.6M -$106.6M 55.14% 55.14% -1221.97% -$112.3M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
FOLD
Amicus Therapeutics
$113.6M -$8M -5.29% -17.7% -5.26% $7.5M
OGN
Organon &
$841M $325M 8.21% 220.72% 14.87% -$22M
PFE
Pfizer
$10.9B $4.4B 5.05% 8.72% 25.08% $1.8B

Arvinas vs. Competitors

  • Which has Higher Returns ARVN or AGIO?

    Agios Pharmaceuticals has a net margin of 43.91% compared to Arvinas's net margin of -1023.25%. Arvinas's return on equity of -7.72% beat Agios Pharmaceuticals's return on equity of 55.14%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- $1.14 $660.6M
    AGIO
    Agios Pharmaceuticals
    87.57% -$1.55 $1.5B
  • What do Analysts Say About ARVN or AGIO?

    Arvinas has a consensus price target of $19.36, signalling upside risk potential of 155.09%. On the other hand Agios Pharmaceuticals has an analysts' consensus of $51.71 which suggests that it could grow by 29.32%. Given that Arvinas has higher upside potential than Agios Pharmaceuticals, analysts believe Arvinas is more attractive than Agios Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    8 9 0
    AGIO
    Agios Pharmaceuticals
    3 3 0
  • Is ARVN or AGIO More Risky?

    Arvinas has a beta of 2.171, which suggesting that the stock is 117.131% more volatile than S&P 500. In comparison Agios Pharmaceuticals has a beta of 0.729, suggesting its less volatile than the S&P 500 by 27.062%.

  • Which is a Better Dividend Stock ARVN or AGIO?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Agios Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or AGIO?

    Arvinas quarterly revenues are $188.8M, which are larger than Agios Pharmaceuticals quarterly revenues of $8.7M. Arvinas's net income of $82.9M is higher than Agios Pharmaceuticals's net income of -$89.3M. Notably, Arvinas's price-to-earnings ratio is -- while Agios Pharmaceuticals's PE ratio is 3.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.28x versus 62.49x for Agios Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    1.28x -- $188.8M $82.9M
    AGIO
    Agios Pharmaceuticals
    62.49x 3.56x $8.7M -$89.3M
  • Which has Higher Returns ARVN or ALNY?

    Alnylam Pharmaceuticals has a net margin of 43.91% compared to Arvinas's net margin of -9.67%. Arvinas's return on equity of -7.72% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- $1.14 $660.6M
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About ARVN or ALNY?

    Arvinas has a consensus price target of $19.36, signalling upside risk potential of 155.09%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $330.77 which suggests that it could grow by 2.47%. Given that Arvinas has higher upside potential than Alnylam Pharmaceuticals, analysts believe Arvinas is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    8 9 0
    ALNY
    Alnylam Pharmaceuticals
    14 7 1
  • Is ARVN or ALNY More Risky?

    Arvinas has a beta of 2.171, which suggesting that the stock is 117.131% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.

  • Which is a Better Dividend Stock ARVN or ALNY?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or ALNY?

    Arvinas quarterly revenues are $188.8M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Arvinas's net income of $82.9M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Arvinas's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.28x versus 17.67x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    1.28x -- $188.8M $82.9M
    ALNY
    Alnylam Pharmaceuticals
    17.67x -- $594.2M -$57.5M
  • Which has Higher Returns ARVN or FOLD?

    Amicus Therapeutics has a net margin of 43.91% compared to Arvinas's net margin of -17.31%. Arvinas's return on equity of -7.72% beat Amicus Therapeutics's return on equity of -17.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- $1.14 $660.6M
    FOLD
    Amicus Therapeutics
    90.66% -$0.07 $584.3M
  • What do Analysts Say About ARVN or FOLD?

    Arvinas has a consensus price target of $19.36, signalling upside risk potential of 155.09%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 160.6%. Given that Amicus Therapeutics has higher upside potential than Arvinas, analysts believe Amicus Therapeutics is more attractive than Arvinas.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    8 9 0
    FOLD
    Amicus Therapeutics
    8 3 0
  • Is ARVN or FOLD More Risky?

    Arvinas has a beta of 2.171, which suggesting that the stock is 117.131% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.181%.

  • Which is a Better Dividend Stock ARVN or FOLD?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or FOLD?

    Arvinas quarterly revenues are $188.8M, which are larger than Amicus Therapeutics quarterly revenues of $125.2M. Arvinas's net income of $82.9M is higher than Amicus Therapeutics's net income of -$21.7M. Notably, Arvinas's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.28x versus 3.42x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    1.28x -- $188.8M $82.9M
    FOLD
    Amicus Therapeutics
    3.42x -- $125.2M -$21.7M
  • Which has Higher Returns ARVN or OGN?

    Organon & has a net margin of 43.91% compared to Arvinas's net margin of 5.75%. Arvinas's return on equity of -7.72% beat Organon &'s return on equity of 220.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- $1.14 $660.6M
    OGN
    Organon &
    55.59% $0.33 $9.5B
  • What do Analysts Say About ARVN or OGN?

    Arvinas has a consensus price target of $19.36, signalling upside risk potential of 155.09%. On the other hand Organon & has an analysts' consensus of $13.33 which suggests that it could grow by 38.46%. Given that Arvinas has higher upside potential than Organon &, analysts believe Arvinas is more attractive than Organon &.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    8 9 0
    OGN
    Organon &
    0 3 0
  • Is ARVN or OGN More Risky?

    Arvinas has a beta of 2.171, which suggesting that the stock is 117.131% more volatile than S&P 500. In comparison Organon & has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ARVN or OGN?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & offers a yield of 8.93% to investors and pays a quarterly dividend of $0.02 per share. Arvinas pays -- of its earnings as a dividend. Organon & pays out 34.38% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ARVN or OGN?

    Arvinas quarterly revenues are $188.8M, which are smaller than Organon & quarterly revenues of $1.5B. Arvinas's net income of $82.9M is lower than Organon &'s net income of $87M. Notably, Arvinas's price-to-earnings ratio is -- while Organon &'s PE ratio is 3.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.28x versus 0.40x for Organon &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    1.28x -- $188.8M $82.9M
    OGN
    Organon &
    0.40x 3.34x $1.5B $87M
  • Which has Higher Returns ARVN or PFE?

    Pfizer has a net margin of 43.91% compared to Arvinas's net margin of 21.63%. Arvinas's return on equity of -7.72% beat Pfizer's return on equity of 8.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- $1.14 $660.6M
    PFE
    Pfizer
    79.26% $0.52 $151.9B
  • What do Analysts Say About ARVN or PFE?

    Arvinas has a consensus price target of $19.36, signalling upside risk potential of 155.09%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    8 9 0
    PFE
    Pfizer
    8 15 1
  • Is ARVN or PFE More Risky?

    Arvinas has a beta of 2.171, which suggesting that the stock is 117.131% more volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

  • Which is a Better Dividend Stock ARVN or PFE?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Arvinas pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or PFE?

    Arvinas quarterly revenues are $188.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Arvinas's net income of $82.9M is lower than Pfizer's net income of $3B. Notably, Arvinas's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 1.28x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    1.28x -- $188.8M $82.9M
    PFE
    Pfizer
    2.25x 17.83x $13.7B $3B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock